Be More Open to New Drugs with Bias Towards Safety

1min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

In dealing with a new disease, it is advisable to be more lenient in assessing the effectiveness of drugs. The focus should be on drugs known to be safe. For instance, early studies on hydroxychloroquine suggested it could be beneficial, thus highlighting the importance of considering various treatment options in the early stages of a disease outbreak.

Jay Bhattacharya is a Professor of Health Policy at Stanford University and a research associate at the National Bureau of Economics Research. He directs Stanford’s Center for Demography and Economics of Health and Aging. His work focuses on the health and well-being of vulnerable populations, with a particular emphasis on the role of government programs, biomedical innovation, and economics. His recent research is on the epidemiology of COVID-19 as well as an evaluation of policy responses to the epidemic.

Shermer and Bhattacharya discuss: loss of trust in medical and scientific institutions • how well did lockdowns and masks really work • Lab Leak vs. Zoonomic hypothesis • hydroxychloroquine & ivermectin • debating anti-vaxxers, RFK, Jr., and conspiracy theories • myocarditis, Robert Malone, mRNA vaccines, Joe Rogan, Peter Hotez • The Great Barrington Declaration • the cost to the economy and education • which countries and states did better or worse.